MBTPS1: A Potential Drug Target Or Biomarker (G8720)
MBTPS1: A Potential Drug Target Or Biomarker
MBTPS1 (Mucin B punctum enzyme-1) is a protein that is expressed in various human tissues, including skin, gut, and breast tissue. It is a member of the punctum enzyme family, which includes a variety of enzymes that play important roles in the regulation of cellular processes such as cell signaling and tissue repair. One of the unique features of MBTPS1 is its ability to cleave the ends of peptides, which is the action that gives it its name.
MBTPS1 has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its ability to cleave peptides has led to the idea that it may be involved in the regulation of signaling pathways that are important for disease progression. Additionally, its expression has been shown to be regulated by a variety of factors, including cell signaling pathways and inflammation.
In cancer, MBTPS1 has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels form in tumors to provide oxygen and nutrients to the growing cells. Studies have shown that MBTPS1 can inhibit the formation of new blood vessels in cancer cells, which may have implications for the development of new treatments for cancer.
In neurodegenerative diseases, MBTPS1 has been shown to be involved in the regulation of axonal transport, which is the process by which nerve cells transport material from the brain to the rest of the body. Studies have shown that MBTPS1 may play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
In autoimmune disorders, MBTPS1 has been shown to be involved in the regulation of immune responses. Studies have shown that MBTPS1 may play a role in the development and regulation of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.
Despite its potential as a drug target or biomarker, MBTPS1 is not yet widely studied, and much more research is needed to fully understand its role in disease. Additionally, the lack of specific inhibitors for MBTPS1 makes it difficult to study its potential as a therapeutic agent.
In conclusion, MBTPS1 is a protein that has been identified as a potential drug target or biomarker for a variety of diseases. Its ability to cleave the ends of peptides and its expression in various tissues make it an attractive candidate for study. Further research is needed to fully understand its role in disease and to develop effective therapeutic agents.
Protein Name: Membrane Bound Transcription Factor Peptidase, Site 1
Functions: Serine protease that cleaves after hydrophobic or small residues, provided that Arg or Lys is in position P4: known substrates include SREBF1/SREBP1, SREBF2/SREBP2, BDNF, GNPTAB, ATF6, ATF6B and FAM20C (PubMed:10644685, PubMed:12782636, PubMed:21719679, PubMed:34349020). Cleaves substrates after Arg-Ser-Val-Leu (SREBP2), Arg-His-Leu-Leu (ATF6), Arg-Gly-Leu-Thr (BDNF) and its own propeptide after Arg-Arg-Leu-Leu (PubMed:10644685, PubMed:21719679). Catalyzes the first step in the proteolytic activation of the sterol regulatory element-binding proteins (SREBPs) SREBF1/SREBP1 and SREBF2/SREBP2 (PubMed:12782636). Also mediates the first step in the proteolytic activation of the cyclic AMP-dependent transcription factor ATF-6 (ATF6 and ATF6B) (PubMed:12782636). Mediates the protein cleavage of GNPTAB into subunit alpha and beta, thereby participating in biogenesis of lysosomes (PubMed:21719679). Cleaves the propeptide from FAM20C which is required for FAM20C secretion from the Golgi apparatus membrane and for enhancement of FAM20C kinase activity, promoting osteoblast differentiation and biomineralization (PubMed:34349020). Involved in the regulation of M6P-dependent Golgi-to-lysosome trafficking of lysosomal enzymes (PubMed:21719679, PubMed:30046013). It is required for the activation of CREB3L2/BBF2H7, a transcriptional activator of MIA3/TANGO and other genes controlling mega vesicle formation (PubMed:30046013). Therefore, it plays a key role in the regulation of mega vesicle-mediated collagen trafficking (PubMed:30046013)
The "MBTPS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MBTPS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MBTPS2 | MC1R | MC2R | MC3R | MC4R | MC5R | MCAM | MCAT | MCC | MCCC1 | MCCC2 | MCCD1 | MCCD1P1 | MCEE | MCEMP1 | MCF2 | MCF2L | MCF2L-AS1 | MCF2L2 | MCFD2 | MCFD2P1 | MCHR1 | MCHR2 | MCHR2-AS1 | MCIDAS | MCL1 | MCM10 | MCM2 | MCM3 | MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20
